FDA Approves First Nalmefene Hydrochloride Auto-Injector to Reverse Opioid Overdose
The U.S. Food and Drug Administration (FDA) has approved Zurnai, a groundbreaking nalmefene hydrochloride auto-injector designed for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients aged 12 years and older. This approval follows the agency’s earlier authorization of the first nasal spray formulation of nalmefene in May 2023. Opioid…